These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23861747)

  • 21. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
    Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A
    Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
    Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
    Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
    Chionh F; Gebski V; Al-Obaidi SJ; Mooi JK; Bruhn MA; Lee CK; Chüeh AC; Williams DS; Weickhardt AJ; Wilson K; Scott AM; Simes J; Hardingham JE; Price TJ; Mariadason JM; Tebbutt NC
    Sci Rep; 2022 Jan; 12(1):1238. PubMed ID: 35075138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
    Duran AO; Karaca H; Besiroglu M; Bayoglu IV; Menekse S; Yapici HS; Yazilitas D; Bahceci A; Uysal M; Sevinc A; Hacibekiroglu I; Aksoy A; Tanriverdi O; Arpaci E; Inanc M; Dane F; Ozkan M
    Asian Pac J Cancer Prev; 2014; 15(23):10375-9. PubMed ID: 25556478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
    Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
    Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang D; Ning Y; Matsusaka S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; West JD; Gopez R; Akihito T; Ichikawa W; Heinemann V; DePaolo RW; Lenz HJ
    Int J Cancer; 2017 Sep; 141(6):1222-1230. PubMed ID: 28569041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
    Koutras AK; Antonacopoulou AG; Eleftheraki AG; Dimitrakopoulos FI; Koumarianou A; Varthalitis I; Fostira F; Sgouros J; Briasoulis E; Bournakis E; Bafaloukos D; Bompolaki I; Galani E; Kalogeras KT; Pectasides D; Fountzilas G; Kalofonos HP
    Pharmacogenomics J; 2012 Dec; 12(6):468-75. PubMed ID: 21844885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
    Clarke S; Burge M; Cordwell C; Gibbs P; Reece W; Tebbutt N
    BMC Cancer; 2013 Mar; 13():120. PubMed ID: 23497305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
    Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
    World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.